Living Cell Technologies Limited
Living Cell Technologies Limited (LVCLY) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
lvcly · pe ratio · data through Jun 10, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Living Cell Technologies LimitedYou LVCLY | $11M | N/A | — | -$0.00 |
 Antibe Therapeutics Inc. ATBPF | $11M | N/A | — | -$0.37 |
 Avecho Biotechnology Limited AVEFF | $11M | N/A | — | -$0.00 |
 Bionomics Limited BNOEF | $9M | N/A | — | -$1898.63 |
 Ceapro Inc. CRPOF | $13M | N/A | — | -$0.06 |
 Eiger BioPharmaceuticals, Inc. EIGRQ | $13M | N/A | — | -$50.78 |
 LexaGene Holdings Inc. LXXGF | $11M | N/A | — | -$0.09 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Living Cell Technologies Limited (LVCLY) measures how much investors pay for each dollar of the company's trailing earnings. LVCLY's current PE ratio of N/A is calculated by dividing its stock price of $0.03 by its TTM earnings per share of -$0.00.
Frequently asked questions
LVCLY pe ratio · 6 questionsLVCLY's current PE ratio is N/A as of 2026-06-10, based on a stock price of $0.03 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via LVCLY's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Living Cell Technologies Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-10